With that, let's consider two dividend-paying companies that look like strong buys for the next two decades: Medtronic ( MDT -0.19%) and Merck ( MRK 3.72%).

While Akeso (AKESF) and Summit Therapeutics’ (SMMT) ivonescimab, a rival to Merck’s (MRK) Keytruda, won approval in China this week, the data on patient survival did not meet analyst expectations, ...

Summit Therapeutics' shares dropped 36% after ivonescimab data showed no significant survival benefit. Click to read if SMMT ...

Akeso has shared for the first time overall survival data from a high-profile Keytruda head-to-head trial for its PD-1xVEGF ...

Keytrda “still reigns” after the interim analysis for Akeso and Summit Therapeutics (SMMT)’ PD-1/VEGF “muddies the outlook” for a potential ivonescimab survival benefit in non-small cell lung cancer.

Akeso, a Chinese biotech that made headlines for beating Merck’s Keytruda in a head-to-head trial, won approval in China this ...

Merck (MRK) stock rises as Summit Therapeutics (SMMT) posts latest survival data for lung cancer therapy ivonescimab ...